Zentalis Pharmaceuticals’ (ZNTL) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report released on Monday morning, Marketbeat Ratings reports. The firm currently has a $10.00 price objective on the stock.

Several other brokerages also recently weighed in on ZNTL. Leerink Partners initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Monday, October 5th. They set an “outperform” rating and a $8.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Friday, October 2nd. Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target on the stock. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, William Blair began coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Zentalis Pharmaceuticals Stock Down 1.3%

ZNTL stock opened at $2.36 on Monday. The business has a 50 day moving average price of $3.19 and a 200 day moving average price of $3.86. The stock has a market cap of $169.14 million, a price-to-earnings ratio of -1.21 and a beta of 1.93. Zentalis Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.11 EPS for the current year.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, major shareholder Group Walters acquired 4,335,000 shares of the stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the transaction, the insider owned 17,844,973 shares of the company’s stock, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ZNTL. 5AM Venture Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the second quarter worth about $19,147,378. BlackRock Inc. purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $18,205,000. Bank of America Corp DE purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $5,406,000. Primecap Management Co. CA purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $4,643,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $3,676,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.